07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

BV-NSCLC-001: Phase III started

Bioven began an open-label, international Phase III trial to evaluate BV-NSCLC-001 plus cyclophosphamide and best supportive care in about 438 patients with inoperable, stage IIIb/IV NSCLC. Bioven has rights to the vaccine from the Center...
07:00 , Jun 14, 2004 |  BioCentury  |  Finance

Ebb & Flow

Packed with paper profits from the run up in cancer stocks over the past year, investors chose to sell into the news coming out of the American Society of Clinical Oncology meeting in New Orleans...
08:00 , Dec 22, 2003 |  BioCentury  |  Finance

Ebb & Flow

Last week's financing activity illustrated the variety of paths companies are taking in this uncertain IPO market. Two companies that had pulled earlier attempts at IPOs took distinctively different paths, with Idenix tossing its hat...
08:00 , Mar 5, 2001 |  BioCentury  |  Finance

Ebb & Flow

While hot life science technologies come and go, VCs are reminding themselves that patience, combined with fundamental investment strategies like targeting big markets, sound management and a solid business plan never go out of style....
08:00 , Jan 8, 1996 |  BioCentury  |  Emerging Company Profile

BioNumerik Pharmaceuticals Inc.

BioNumerik Pharmaceuticals Inc. San Antonio, Texas Technology: Drug discovery using parallel supercomputers and molecular simulation software Founded: 1992 by Frederick Hausheer University collaborators: The Johns Hopkins Oncology Center, Lawrence Livermore Labs, Roswell Park Cancer Institute,...